Advertisement
Organisation › Details
Voluntis (Group)
Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to the patient and the care team so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. These real-time recommendations are based on digitized clinical algorithms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in diabetes and oncology. Voluntis has long-standing partnerships with leading life science companies. Based out of Boston and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance. *
Start | 2001-11-05 established | |
Industry | healthcare informatics | |
Industry 2 | digital therapeutic (dTx) | |
Person | Leurent, Pierre (Voluntis 201805 CEO + Co-Founder) | |
Region | Paris | |
Country | France | |
Street | 22 quai Gallieni | |
City | 92150 Suresnes | |
Tel | +33-1-4138-3920 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | C: 51 to 100 (2021-06-22) |
Currency | EUR | |
Annual sales | 5,170,000 (income, total, consolidated (2018) 2018-12-31) | |
Profit | -15,935,000 (2018-12-31) | |
Cash | 19,783,000 (2018-12-31) | |
* Document for »About Section«: Voluntis S.A.. (12/18/19). "Press Release: Voluntis Announces New Pharma Collaboration in Oncology". Cambridge, MA & Paris. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Voluntis (Group)
- [1] Voluntis S.A.. (7/23/21). "Press Release: Voluntis Announces the Execution of a Share Purchase Agreement between Its Reference Shareholders and Aptar Regarding the Acquisition of a Majority Stake in Voluntis at a Price of €8.70 per Share". Cambridge, MA...
- [2] Voluntis S.A.. (6/22/21). "Press Release: Exclusive Negotiations Regarding a Potential Acquisition of Voluntis by Aptar to Expand in Digital Therapeutics". Cambridge, MA & Paris....
- [3] Voluntis S.A.. (11/23/20). "Press Release: Voluntis Successfully Completes a Capital Increase of €5.9 Million and Finalizes the Financing of Its Strategic Roadmap [Not for US, CA, AU or JP] Japan.". Cambridge, MA & Paris....
- [4] Voluntis S.A.. (3/4/20). "Press Release: Voluntis Announces Its New Strategic Roadmap. Strategic Prioritization of the Oncology Business". Cambridge, MA & Paris....
- [5] Voluntis S.A.. (3/3/20). "Press Release: Voluntis and Bristol-Myers Squibb to Co-develop Digital Therapeutics for Oncology". New York, NY & Paris....
- [6] Voluntis S.A.. (12/18/19). "Press Release: Voluntis Announces New Pharma Collaboration in Oncology". Cambridge, MA & Paris....
- [7] Voluntis S.A.. (12/16/19). "Press Release: Voluntis Collaborates with Salesforce to Introduce Full-Service Platform for Digital Therapeutics Prescription and Reimbursement". Cambridge, MA & San Francisco, CA....
- [8] Euronext N.V.. (5/30/18). "Press Release: Digital Biotech Voluntis Lists on Euronext". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top